Tenecteplase shortage to continue

alert shortage warning
Boehringer Ingelheim has notified the TGA that its tenecteplase shortage will continue until the end of next year In August 2022, BI had told the Therapeutic Goods Administration that the thrombolytic was in shortage, due to manufacturing capacity constraints following increases in global demand. The shortage was expected to continue until the end of 2023

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Greenwood to leave Guild
Next Commercial training, too many apprentices and cocaine